[Skip to Content]

Claim CME

Vaccination

Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA

Published Online: April 22, 2022

Research Letter

Article Information and Disclosures

Hilda Razzaghi, PhD¹;

Mehreen Meghani, MPH²;

Bradley Crane, MS³;

Sascha Ellington, PhD⁴;

Allison L. Naleway, PhD³;

Stephanie A. Irving, MHS³;

Suchita A. Patel, DO¹

Author Affiliations

¹National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia
²US Centers for Disease Control and Prevention Foundation, Atlanta, Georgia
³Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon
⁴National Center for Chronic Disease Prevention and Health Promotion, US Centers for Disease Control and Prevention, Atlanta, Georgia

Read article on JAMA Network

Read Article Claim CME

Booster doses of COVID-19 vaccines were recommended for people aged 18 years or older in November 2021 following the recommendation of an additional primary dose of COVID-19 vaccine for select immunocompromised populations on August 13, 2021.¹ As of February 26, 2022, more than 93 million booster doses of COVID-19 vaccines had been administered in the US²; however, data on receipt of booster doses among pregnant individuals are lacking. We present findings on receipt of booster doses among pregnant individuals in the Vaccine Safety Datalink (VSD).

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: April 11, 2022.

Published Online: April 22, 2022. doi:10.1001/jama.2022.6834

Corresponding Author: Hilda Razzaghi, PhD, US Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-4, Atlanta, GA 30329 (hrazzaghi@cdc.gov).

Author Contributions: Ms Meghani and Mr Crane had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Razzaghi, Meghani, Ellington.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Meghani, Crane.

Obtained funding: Irving.

Administrative, technical, or material support: Razzaghi, Meghani, Ellington, Irving, Patel.

Supervision: Razzaghi, Ellington, Patel.

Conflict of Interest Disclosures: Dr Naleway reported receiving grants from Pfizer and Vir Biotechnology. No other disclosures were reported.

Funding/Support: This study was funded by the US Centers for Disease Control and Prevention (CDC).

Role of the Funder/Sponsor: The CDC participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC.

Additional Contributions: We thank Eric Weintraub, MPH (CDC), for assistance with data collection and management in addition to administrative and technical support; James Singleton, PhD (CDC), for technical assistance; and the Leidos Data Science Team at the National Center for Immunization and Respiratory Diseases for data processing and management. We thank the following Vaccine Safety Datalink partners: Tia Kauffman, MPH (Kaiser Permanente Northwest); Malini DeSilva, MD, MPH, and Gabriela Vazquez-Benitez, PhD (both with HealthPartners); Heather Lipkind, MD, MS (Yale University); Ousseny Zerbo, PhD (Kaiser Permanente Northern California); Matthew Daley, MD (Kaiser Permanente Colorado); Darios Getahun, MD, PhD, and Sungching Glenn, MS (both with Kaiser Permanente Southern California); Jennifer Nelson, PhD (Kaiser Permanente Washington); Simon Hambidge, MD, PhD (Denver Health); and Kayla Hanson, MPH (Marshfield Clinic), for providing subject matter expertise, technical assistance, assistance with data collection, and review of the study. No compensation was received by the individuals named in this section.

References

US Centers for Disease Control and Prevention. CDC expands eligibility for COVID-19 booster shots to all adults. Accessed January 22, 2022. https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html

US Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Accessed December 9, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-onedose-pop-5yr

Naleway AL , Crane B , Irving SA , et al. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021;12:20420986211021233. doi:10.1177/20420986211021233 PubMed Google Scholar Crossref

Sukumaran L , McCarthy NL , Li R , et al. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): a comparison with the United States population. Vaccine. 2015;33(36):4446-4450. doi:10.1016/j.vaccine.2015.07.037 PubMed Google Scholar Crossref

Fell DB , Dhinsa T , Alton GD , et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. Published online March 24, 2022. doi:10.1001/jama.2022.4255 PubMed Google Scholar Crossref

Magnus MC , Örtqvist AK , Dahlqwist E , et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. Published online March 24, 2022. doi:10.1001/jama.2022.3271 PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.